Evaluation of Biosimilars for Formulary Inclusion: Factors for Consideration by P&T Committees.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. An Institutional Guide for Formulary Decisions of Biosimilars.Hospital pharmacy · 2023
   Review
2. Practical Strategies for Advanced Practitioners Streamlining the Integration of Oncology Biosimilar Therapies Into Practice.Journal of the advanced practitioner in oncology · 2022
   Review
3. Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022
   Article
4. Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives.Applied health economics and health policy · 2021
   Article
5. Effect on Patients' Outcomes of a Change to Biosimilar Filgrastim Product in Autologous Stem Cell Mobilization.The Canadian journal of hospital pharmacy · 2021
   Article
6. Considerations for the US health-system pharmacist in a world of biosimilars.Drugs in context · 2020
   Article
7. The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy.Biomolecules · 2019
   Review
8. Biosimilars: Considerations for Payers.P & T : a peer-reviewed journal for formulary management · 2019
   Article
9. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.Drugs · 2017
   Review
10. Biosimilar Drugs and the Hospital Formulary: A Canadian Experience.The Canadian journal of hospital pharmacy
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract